SUMMARY

Forty patients received tubocurarine in a dose greater than ED go . When neuromuscular function had recovered to amplitude of the first contraction of the train-of-four equals 10% of control, a small increment of atracurium or vecuronium was administered, repeating the same increment at each subsequent recovery to 10%. The intensity and duration of the neuromuscular block following the first increment was always greater than that of subsequent increments. The duration and intensity of the block was progressively reduced with subsequent increments until the responses to further in
to the hand and wrist. The compound evoked electromyogram was recorded over the adductor pollicis muscle after stimulation of the ulnar nerve (Datex Relaxograph). Anaesthesia was induced using thiopentone 4 mg kg" 1 and fentanyl 2 ug kg" 1 and ventilation controlled with 67 % nitrous oxide in oxygen to maintain normocapnia.
Neuromuscular function was monitored continuously throughout anaesthesia using trains of four supramaximal stimuli every 20 s. After baseline measurements of neuromuscular function, an initial dose of tubocurarine 0.35 mg kg" 1 was given. Additional increments of tubocurarine 0.05 mg kg" 1 were given in close succession, if needed, until neuromuscular block exceeded 90%. The trachea was intubated and controlled ventilation, maintaining normocapnia, continued using 67 % nitrous oxide in oxygen. Further doses of fentanyl to a maximum of 10 ug kg" 1 were administered as required during the procedure, together with droperidol to a maximum of 10 mg. Continuous ECG and pulse wave were monitored during operation. Arterial pressure was measured automatically (Dinamap). When neuromuscular function had recovered such that the amplitude of the first contraction of the train-offour (Tl) had reached 10% of control, an increment of atracurium or vecuronium was given. At each subsequent Tl recovery to 10% the same dose of the same drug was administered.
Patients were allocated randomly to one of four groups: groups 1 and 2 received increments of atracurium 1.1 mg or 2 mg, respectively; groups 3 and 4 received increments of vecuronium 0.25 mg or 0.5 mg, respectively. Atracurium 1.1 mg and vecuronium 0.25 mg increments were chosen because they are equipotent at the 90% level of neuromuscular block [5] . Vecuronium 0.5 mg was chosen because it was twice the dose given to group 3, and for comparison with previous studies. Atracurium 2 mg was chosen as a convenient dilution of the agent which approximated to twice the dose used in group 1. Following each increment of atracurium or vecuronium, maximum Tl depression and the time to achieve maximum neuromuscular block were recorded. The duration of effect of each increment was also recorded, as measured by the return of Tl to 10%. At the termination of surgery, all patients received i.v. glycopyrrolate 0.01 ng kg" 1 and neostigmine 0.05 ug kg" 1 to accelerate recovery of neuromuscular function.
A supply of atracurium ampoules which had been maintained refrigerated from manufacture was used. Both atracurium and vecuronium were diluted freshly with 5 % dextrose for each subject.
All drugs were administered into a fast-running i.v. infusion.
Statisical analysis
The age, weight, dose of tubocurarine and duration of those doses were compared between groups, using one-way analysis of variance. These four variables were considered as potential covariates in subsequent analyses. The remaining data were found to conform to a log-normal distribution, and this transformation was used for subsequent data analysis. Analysis of variance was performed to determine the presence of any significant difference between the groups and between increments within the groups. Tukey's range test was used to identify the source of those significant differences.
RESULTS
The mean ages and weights of the patients in the four groups did not differ significantly (table I) . The dose of tubocurarine required to achieve a greater than 90% neuromuscular block was between 0.35 mg kg" 1 and 0.70 mg kg" 1 . These The mean maximum neuromuscular block resulting from each increment, together with the times to achieve this maximum for all groups are shown in table III. Analysis of the maximum depression showed that there were significant effects of three of the covariates on this variable. The maximum Tl depression increased with the weight of the patient and with the dose of tubocurarine and decreased with the duration of the tubocurarine dose. The means as presented in table III are therefore adjusted for these three covariates. In every case, the first increment had the greatest effect, reducing successively with the following increments. In most instances the maximum depression with vecuronium was greater than with the corresponding atracurium increments (groups 1 and 3 compared; groups 2 and 4 compared). The times to reach maximum Tl depression in the atracurium groups were significantly less than the vecuronium groups for most increments. There was little change in the times to maximum Tl depression within the groups.
Using the duration of action of each increment in each group at steady state and the mean weight of the patients in the four groups, the average rate of use of each agent was calculated (table IV) . DISCUSSION The overall mean intubating dose of tubocurarine, 0.45 mg kg" 1 (range 0.35-0.7), resulted in a mean maximum neuromuscular block of 97% (range 93-100). This agrees well with data from previous studies in which the ED 95 for tubocurarine has been reported to be between 0.34 and 0.56 mg kg" 1 (mean of 0.48 mg kg" 1 ) [6] .
Following the intubating dose of tubocurarine, the great majority of neuromuscular receptors are occupied by tubocurarine molecules and at 90 % neuromuscular block (10% recovery) they are still occupied predominantly by tubocurarine molecules. The addition of a small increment of either atracurium or vecuronium at that point would be expected to result in a further increase in receptor occupancy. This increase in receptor occupancy by antagonist molecules is likely to lead to an increase in neuromuscular block. The identical increments of atracurium or vecuronium add each time a similar amount to the increasing concentration of the second agent in plasma and at the receptor site. Assuming that both agents possess first order pharmacokinetics, this change in concentration is greatest with the first increment as the concentration increases from zero and reduces with successive increments. The effects of earlier increments should therefore last longer than later increments. It is possible that the decrease in duration of effect from the first increment is at least partly a result of this principle.
The action of the tubocurarine continues to wane with time as molecules leave the region of the neuromuscular junction. The rate of loss of tubocurarine molecules from the region of the neuromuscular junction also changes with time and in an exponential fashion. Initially, recovery is likely to result from removal of tubocurarine molecules. With time, the recovery from each increment should be less because of clearance of tubocurarine and more because of clearance of the second agent. Ultimately, the situation might present where molecules of both agents are leaving at approximately the same rate as molecules of the shorter acting agent are arriving and, under these circumstances, identical increments should have an identical action. At this steady state, a significant proportion of receptors must still be occupied by tubocurarine (or some other residual effect of tubocurarine persist), otherwise there is no reason why such a small dose of atracurium or vecuronium should produce a neuromuscular block in excess of 90%.
In a system where there is competitive interaction at a single receptor site the observed effect, as a proportion of the maximum possible effect, is proportional to receptor occupancy. Identical amounts of an antagonist add identical numbers of molecules to the biophase and thus should produce an identical change from a given point in the system. In the present study, successive increments did not produce identical effects. Furthermore, the extension of neuromuscular block and the intensity of effect were greater with vecuronium than with an equipotent dose of atracurium. Such an observation cannot be explained fully by simple interaction at one receptor site or by the pharmacokinetic effects discussed previously. In addition, any action of the second agent on the receptor affinity of the first is not known. Evidence exists to suggest that the neuromuscular junction is not a simple receptor system and it is likely, therefore, that the three agents, tubocurarine, atracurium and vecuronium, are all acting in slightly different ways. Previous reports have suggested that the combination of tubocurarine with some other neuromuscular blocking agents may not lead to simple addition of action [7, 8] .
Significant effects were observed of three covariates on the maximum depressions resulting from each increment. It is difficult to be certain of the mechanisms involved. The maximum Tl depression increased with increasing weight of the patients. Although no measures were taken of height or body fat content (all patients were female) larger patients should have a greater distribution volume and therefore a small fixed increment would be expected to have less, not greater effect. The maximum Tl depression increased also with the dose of tubocurarine and decreased with time before return to 10%. Following a larger initial dose of tubocararine (on an mg kg" 1 basis) or where less time has elapsed since the intubating dose, the quantity of tubocurarine in the active biophase when the first increment was given would be expected to be greater. This does, however, discount binding to extrajunctional receptors, elimination and other distribution effects, all of which play an important and unquantifiable role.
The rates of use of both atracurium and vecuronium have been calculated at steady state. If one of these two is used as sole neuromuscular blocking agent, the rate of use for the maintenance of 90-95 % neuromuscular block would be expected to be approximately 0.366-0.432 mg kg" 1 h" 1 for atracurium and 0.055-0.102 mg kg" 1 h" 1 for vecuronium [6] . It is clear, therefore, that the presence of a partial tubocurarine block would reduce considerably the rate of consumption of both atracurium and vecuronium. These results may be viewed in two ways. On the one hand, the action of a small dose of atracurium or vecuronium is increased in the presence of a tubocurarine-induced neuromuscular block. On the other, a tubocurarine-induced neuromuscular block may be usefully extended by very small doses of either atracurium or vecuronium. Whichever view is taken, this technique is attractive and has proved convenient in regular clinical use.
